Capmatinib, should I take 2 or 4 pills a day?
Capmatinib (Capmatinib) is for oral use in the form of oval, curved film-coated tablets with beveled edges, unpackaged, containing 150 mg (light orange-brown) or 200 mg (yellow) Capmatinib (equivalent to 183.00 mg or 244.00 mg Capmatinib dihydrochloride monohydrate, respectively). Capmatinib is a drug used to treat certain types of cancer, such as non-small cell lung cancer, and its dosage and usage are usually determined based on the patient's specific situation and the advice of their doctor.

The dose of capmatinib is based on a variety of factors, including the patient's weight, severity of illness, use of other medications, and the patient's overall health. Doctors will use these factors to evaluate a patient's specific situation and determine the most appropriate dosage. As a prescription drug, capmatinib should be used according to the doctor's recommendations and the instructions in the drug package insert. Patients should not decide the dosage and usage of drugs by themselves to avoid adverse reactions or affecting the effectiveness of treatment.
According to the clinical guidelines of capmatinib, the recommended dose is 400 mg taken orally twice daily (two 200 mg capmatinib tablets can be taken). Capmatinib is a selective ib-type ATP competitive tyrosine kinase inhibitor that targets MET. Capmatinib has an mean IC50 value of 0.13 nM in lung cancer cell lines and exhibits linear pharmacokinetics, with exposure increasing approximately in a dose-proportional manner over the dose range of 200-400 mg. It is rapidly absorbed, reaching peak plasma concentration (Cmax) approximately 1-2 hours after a 400 mg dose. There is similar absorption with and without food. The effective elimination half-life is 6.5 hours. Plasma protein binding rate is 96%.
In summary, the dosage and usage of capmatinib should be determined based on the patient's specific condition and physician recommendations. Patients should follow their doctor's instructions and communicate with their doctor regularly to ensure the effectiveness and safety of treatment.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)